A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme

Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor. Despite the advances in surgery, radiotherapy and chemotherapy, patient survival averages only 14.6 months. In most GBM tumors, tyrosine kinases show increased activity and/or expression and actively contribute to t...

Descripción completa

Detalles Bibliográficos
Autores principales: Nehoff, Hayley, Parayath, Neha N., McConnell, Melanie J., Taurin, Sebastien, Greish, Khaled
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741976/
https://www.ncbi.nlm.nih.gov/pubmed/26517812

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741976/
https://www.ncbi.nlm.nih.gov/pubmed/26517812

Ejemplares similares